[ad_1]
An aggressive and rare form of cancer, mesothelioma develops in the lining of the stomach, heart, etc., but according to health experts, it mainly affects the lining of the lungs. Can also affect. Or testicles. It is usually associated with exposure to asbestos in the workplace and is difficult to treat or may not be curable, although treatment can help control fatal symptoms.
Thousands of people are diagnosed with the disease globally each year, and mesothelioma has one of the worst cancer survival rates in the world, but there is a ray of hope for patients as UK scientists find a cure for this aggressive asbestos-related cancer. The new drug is being hailed as “truly wonderful”. Which resulted in a successful clinical trial. Recent clinical trials show promising results of combining ADI-PEG20 with chemotherapy for malignant mesothelioma patients and this is indeed a significant advancement in the field of oncology.
The study was published in JAMA Oncology and this collaborative effort led by Queen Mary University of London and the University of Western Australia underlines the global impact of this breakthrough as the international trial continues in five countries with patients from the UK, US, Australia, Italy and Was spread. Taiwan revealed between 2017 and 2021 that a new drug that cuts off tumors’ food supply quadrupled three-year survival rates. This innovative approach demonstrates the potential to increase survival rates and marks a turning point in the fight against mesothelioma.
“In this pivotal, randomized, placebo-controlled, phase 3 trial in 249 patients with pulmonary mesothelioma, pegargiminase-chemotherapy significantly extended median overall survival by 1.6 months,” wrote the authors, including Queen Mary’s Professor Peter Szlosarek, who led the research. increased and quadrupled the survival rate at 36 months compared to placebo-chemotherapy. Pegargiminase-based chemotherapy was well tolerated without any new safety signals.
In an interview with HT Lifestyle, Dr. Jyoti Mehta, MD, Radiation and Clinical Oncologist at TGH OncoLife Cancer Center in Talegaon, stressed, “The success of this clinical trial increases optimism within the scientific community, highlighting the importance of collaborative research and discovery. emphasizes on. of novel treatment strategies. The integration of ADI-PEG20 with chemotherapy offers a ray of hope for patients battling lethal mesothelioma, demonstrating the potential for improved outcomes and improved quality of life.
He stressed, “While further studies and clinical validation will be important, these early findings underscore the importance of continued investment in research and development to bring transformative solutions to challenging medical conditions. The scientific community is eagerly awaiting more detailed information about the mechanisms and long-term effects of ADI-PEG20, with the hope that it may emerge as a truly wonderful advancement in the asbestos-associated cancer treatment landscape.
[ad_2]
